Last reviewed · How we verify
ceftriaxone and azithromycin
This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a macrolide antibiotic to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens.
This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a macrolide antibiotic to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens. Used for Community-acquired pneumonia, Respiratory tract infections, Atypical pneumonia.
At a glance
| Generic name | ceftriaxone and azithromycin |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | Beta-lactam antibiotic and macrolide antibiotic combination |
| Target | Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftriaxone is a beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Azithromycin is a macrolide that binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis. Together, they provide synergistic activity against common respiratory bacteria including Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms like Mycoplasma and Chlamydia.
Approved indications
- Community-acquired pneumonia
- Respiratory tract infections
- Atypical pneumonia
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Rash
- Headache
- Vomiting
- QT prolongation (azithromycin)
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Zoliflodacin in Uncomplicated Gonorrhoea (PHASE3)
- Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (NA)
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea (PHASE3)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ceftriaxone and azithromycin CI brief — competitive landscape report
- ceftriaxone and azithromycin updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI